Molecular approaches to sarcoma therapy

Sarcoma

Volumn 6, Issue 1, 2002, Pages 27-42

  Olsen, R J ^a   Tarantolo, S R ^b   Hinrichs, S H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Fusion protein; Molecular therapy; Sarcoma; Translocation

Indexed keywords

HYBRID PROTEIN; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL TYPE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; OUTCOMES RESEARCH; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; SARCOMA; TRANSLATION REGULATION;

EID: 0036276451     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140220127530     Document Type: Article

References (189)

1. A genetic model for colorectal tumorigenesis
2. Contribution of molecular genetic data to the classification of sarcomas
3. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
4. New diagnostic modalities in soft tissue sarcoma
5. Clinically critical impact of molecular genetic studies in pediatric solid tumors
6. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma
7. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma
8. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma
9. Prognostic impact of P53 status in Ewing sarcoma
10. Cytogenetics and the biological basis of sarcomas
11. Fusion genes in solid tumors
12. Immunotherapeutic approaches to sarcoma
13. New chemotherapeutic strategies for soft tissue sarcomas
14. Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma
15. Soft tissue sarcomas
16. Adjuvant chemotherapy for soft-tissue sarcoma: Review and meta-analysis of the published results of randomised clinical trials
17. Clear cell sarcoma of soft tissues in children and young adults: The St. Jude Children's Research Hospital experience
18. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group
19. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients
20. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma
21. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities
22. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
23. All-trans-retinoic acid in acute promyelocytic leukemia
24. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
25. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
26. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy
27. Molecular alterations in pediatric sarcomas: Potential targets for immunotherapy
28. Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein
29. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation
30. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein
31. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias
32. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene
33. Cytogenetics and experimental models
34. Molecular genetics of chromosome translocations involving EWS and related family members
35. Clinical relevance of molecular diagnosis in childhood rhabdomyosarcoma
36. Coupling gene expression to cAMP signalling: Role of CREB and CREM
37. The Ewing family of tumors and the search for the Achilles' heel
38. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family
39. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts
40. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells
41. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro
42. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides
43. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice
44. Chromosomal abnormalities in clear cell sarcoma
45. Cytogenic findings in clear cell sarcoma of tendons and aponeuroses ('malignant melanoma of soft parts')
46. Transcriptional inhibition by a monoclonal antibody Fab fragment
47. Inhibition of activating transcription factor 1- and cAMP-responsive element-binding protein-activated transcription by an intracellular single chain Fv fragment
48. Regulating the neoplastic phenotype using engineered transcriptional repressors
49. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins
50. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene
51. The regulation of transcription by phosphorylation
52. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling
53. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: Therapeutic implications
54. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells
55. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors
56. Researchers buoyed by promise of targeted leukemia therapy
57. Genetics and the biologic basis of sarcomas
58. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement
59. STI571, an active drug in metastatic gastrointestinal stroma tumors (GIST), an EORTC phase I study
60. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571 in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) expressing D-KIT
61. Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins
62. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma
63. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma
64. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?
65. Human mesenchymal tumors: Concepts in pathology and biology
66. Engineered mutants of pRB with improved growth suppression potential
67. Restoration of transcriptional activity of p53 mutants in human turnout cells by intracellular expression of anti-p53 single chain Fv fragments
68. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas
69. Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas
70. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas
71. Clinical relevance of pRb and p53 co-overexpression in soft tissue sarcomas
72. pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels
73. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas
74. Database of p53 gene somatic mutations in human tumors and cell lines: Updated compilation and future prospects
75. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
76. Mutant p53 expression: A marker of diminished survival in well-differentiated soft tissue sarcoma
77. p21ras signaling is necessary but not sufficient to mediate neurotrophin induction of calcium channels in PC12 cells
78. Soft tissue sarcomas and p53 mutations
79. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control
80. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity
81. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
82. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression
83. Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression
84. Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2
85. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: No simultaneous alterations in the oncogenesis of liposarcomas
86. Amplification of the c-myc proto-oncogene in soft tissue sarcomas
87. mdm2: A bridge over the two tumour suppressors, p53 and Rb
88. The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
89. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins
90. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein
91. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene
92. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
93. Angiogenesis in cancer, vascular, rheumatoid and other disease
94. Vascular-specific growth factors and blood vessel formation
95. Tumor angiogenesis: Therapeutic implications
96. Angiogenesis and angiogenesis inhibition: An overview
97. Angiogenesis in cancer and other diseases
98. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor
99. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
100. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
101. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
102. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: Effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts
103. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma
104. Tumour vasculature as a target for anticancer therapy
105. Clinical strategy for the development of angiogenesis inhibitors
106. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
107. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids
108. Experimental study of the therapeutic effects of an anti-endothelial cell monoclonal antibody BVE-1 for solid tumor xenograft in nude mice
109. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
110. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
111. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection
112. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
113. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
114. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B
115. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha
116. Apoptosis
117. Immunohistology of neuroendocrine and neuroectodermal tumors
118. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis
119. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion
120. Apoptosis of immature thymocytes mediated by E2/CD99
121. CD99 engagement: An effective therapeutic strategy for Ewing tumors
122. MIC2 detection in tumors of bone and adjacent soft tissues
123. Progress in the molecular biology of Ewing tumors
124. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells
125. Angiomatoid (malignant) fibrous histiocytoma: A peculiar low-grade tumor showing immunophenotypic heterogeneity and ultrastructural variations
126. Primary synovial sarcoma of the kidney
127. A case of soft tissue mesenchymal chondrosarcoma metastatic to skin, clinically mimicking keratoacanthoma
128. Synovial sarcoma
129. Intraabdominal desmoplastic small round cell tumor with EWS/ERG fusion transcript
130. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
131. The Fas death factor
132. Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma
133. Modulation of fas-mediated apoptosis in osteosarcoma cell lines
134. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts
135. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy
136. Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: Novel biological tools for controlling apoptosis in vivo
137. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases
138. Rel/NF-kappa B transcription factors and the control of apoptosis
139. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression
140. Inhibition of the transcription factor nuclear factor-kappa B by adenoviral-mediated expression of I kappa B alpha M results in tumor cell death
141. Regulation of E2F: A family of transcription factors involved in proliferation control
142. Induction of apoptosis in a leiomyosarcoma cell line by adenoviral-mediated over-expression of the transcription factor E2F-1
143. Preclinical experimental therapeutic approaches in soft tissue sarcoma
144. Growth inhibition of leiomyosarcoma in vivo using an adenovirus overexpressing the transcription factor E2F-1
145. Functions of fibroblast growth factors in vertebrate development
146. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma
147. Does death receptor signaling play a role in tumorigenesis and cancer therapy?
148. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines
149. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)
150. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
151. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
152. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial
153. Molecular diagnosis and gene therapy in musculoskeletal tumors
154. Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer
155. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma
156. Connexin 43-enhanced suicide gene therapy using herpesviral vectors
157. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
158. Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells
159. Intratumor administration of fusogenic liposomes containing fragment A of diphtheria toxin suppresses tumor growth
160. Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy
161. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
162. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11
163. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia
164. Restoration of tumour suppressor gene expression for cancer
165. Prognostic impact of INK4A deletion in Ewing sarcoma
166. p53 tumor suppressor gene therapy for cancer
167. DNA-carrier proteins for targeted gene delivery
168. Continuous cultures of fused cells secreting antibody of predefined specificity
169. Clinical trials of Herceptin(trastuzumab)
170. The Nobel lectures in immunology. The Nobel prize for physiology or medicine, 1908, awarded to Elie Metchnikoff & Paul Ehrlich "in recognition of their work on immunity "
171. From the molecule to the clinic-inhibiting HER2 to treat breast cancer
172. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
173. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
174. Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermanl Growth Factor Receptor (EGFR)
175. Technology evaluation: Gemtuzumab ozogamicin, Celltech Group
176. A Phase II study of Bexxar (Tositumomab and I-131 Tositumomab) for Patioents at 1st or 2nd Recurrence of B-Cell Non Hodgkin's Lymphoma
177. Zevalin Radioimmunotherapy (RIT) is safe and effective in geriatric patients with Low Grade Follicular or CD20+ Transformed (LG/F/T) Non-Hodgkin's Lymphoma
178. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli
179. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
180. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
181. Engineering monoclonal antibodies
182. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application
183. Stability engineering of antibody single-chain Fv fragments
184. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data
185. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma